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Abstract
Background: Methotrexate (MTX) is the most commonly prescribed disease-modifying antirheumatic drug
(DMARD) in rheumatoid arthritis. ATP-binding cassette transporter-A1 (ABCA1) and 27-Hydroxylase (HY27) are
known antiatherogenic proteins that promote cellular cholesterol efflux. In THP-1 macrophages, MTX can promote
the reversal of cholesterol transport, limit foam cell formation and also reverse COX-2 inhibitor-mediated
downregulation of ABCA1. Despite its antiatherogenic potential in vitro, the impact of clinical use of low-dose MTX
on cholesterol metabolism in humans is unknown. Objective of the study was to examine whether clinical MTX
use is associated with altered blood lipids and/or ABCA1/HY27 expressions.
Methods: In all, 100 rheumatoid arthritis subjects were recruited from a medical center in central Taiwan. Plasma
lipid profiles and peripheral blood mononuclear cell HY27 and ABCA1 expressions were compared between
subjects taking MTX (MTX+) and other disease-modifying antirheumatic drugs (DMARDs) (MTX-). Dietary intake was
assessed by a registered dietician.
Results: Though no difference observed in the blood lipids between MTX+ and MTX- subjects, the expressions of
ABCA1 and HY27 were significantly elevated in MTX+ subjects (n = 67) compared to MTX- subjects (n = 32, p <
0.05). ABCA expression correlated with MTX doses (r = 0.205, p = 0.042), and MTX+ subjects are more likely to have
increased HY27 compared to MTX- subjects (OR = 2.5, p = 0.038). Prevalence of dyslipidemia and overweight, and
dietary fat/cholesterol intake were lower than that of the age-matched population. Although no differences were
observed in the blood lipids, the potential impacts of MTX on cholesterol metabolism should not be overlooked
and the atheroprotective effects from MTX induced HY27 and ABCA1 expressions may still be present in those
persons with pre-existing dyslipidemia.
Conclusions: We demonstrated novel findings on the increased gene expressions of atheroprotective protein HY27
and ABCA1 in human peripheral blood mononuclear cells (PBMCs) with clinical use of low-dose MTX. Whether MTX
induced HY27 and ABCA1 expressions can protect against cardiovascular disease in patients with chronic
inflammation through the facilitation of cholesterol export remains to be established. Further studies on the
impacts of low-dose MTX on hypercholesterolemic patients are underway.
* Correspondence: chiangisabel@nchu.edu.tw
Department of Food Science & Biotechnology, National Chung Hsing
University, Taichung, Taiwan
Chen et al. BMC Medicine 2011, 9:4
http://www.biomedcentral.com/1741-7015/9/4
© 2011 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Methotrexate (MTX) is the most commonly prescribed
disease-modifying antirheumatic drug (DMARD) for
human rheumatoid arthritis. MTX is a folate antagonist
that inhibits dihydrofolate reductase activity and is used
for its anti-inflammatory and immunosuppressive prop-
erties in rheumatoid arthritis [1]. MTX blocks a number
of enzymes involved in purine and pyrimidine metabo-
lism. MTX promotes adenosine release and adenosine,
acting at its receptors, mediates the immunologic and
anti-inflammatory effects of MTX in the treatment of
rheumatoid arthritis [2-4].
Dyslipidemia is the elevation of plasma cholesterol, tri-
glycerides, or a low/high density lipoprotein that usually
results from excessive dietary intake of saturated fat,
cholesterol, or trans fats. We recently discovered in a
pilot study that some arthritis patients on low dose
MTX had altered blood lipids compared to those not
taking methotrexate [5]. We postulated that these
altered blood lipid profile is related to the changes in
ATP-binding cassette transporter A1 (ABCA1) and
27-hydroxylase (HY27), as a previous in vitro study
reported that MTX induced HY27 expression and
reversed cyclo-oxygenase 2 (COX-2) inhibitor-mediated
downregulation of ABCA1 in a macrophage cell model.
The mitochondrial cytochrome P-450 sterol HY27
catalyzes the initial oxidation steps in the bile acid
synthesis from cholesterol [6]; ABCA1 is a cell mem-
brane-bound protein responsible for the secretion of
excess cholesterol, phospholipids, and other lipophilic
molecules across the plasma membrane from cells. Both
HY27 and ABCA1 play crucial roles in cholesterol meta-
bolism in most tissues of the body [7].
Atherosclerosis contributes to cardiovascular disease
(CVD), morbidity, and mortality in autoimmune dis-
eases, including: systemic lupus erythematosus and
rheumatoid arthritis [8]. Impaired cholesterol homeosta-
sis has been reported in patients with rheumatoid arthri-
tis and lupus erythematosus [8-10]. Incubation of
systemic lupus erythematosus in patients’ plasma signifi-
cantly decreased the expression of HY27 in THP-1
human monocytes and further increased the THP-1
macrophage foam cell transformation from monocytes
[ 1 1 ] .T h e s er e s u l t si m p l yar o l eo fi m m u n ed y s f u n c t i o n
in human atherogenesis, and certain immunological
mediators may perturb the cholesterol homeostasis in
human monocytes/macrophages and endothelium. By
inhibiting the inflammatory response, MTX and other
DMARDs may reduce the risk of CVD by decreasing
the exposure of atherogenic mediators in these patients.
In vitro MTX treatment increases HY27 mRNA expres-
sion and blocks COX2 inhibitor-induced downregulation
of HY27 in human THP-1 monocyte/macrophages [12].
In THP-1 macrophages MTX has been reported to
promote the reversal of cholesterol transport through
adenosine A2A receptor activation and limits foam cell
formation [12]. In addition, MTX reverses COX-2 inhibi-
tor-mediated downregulation of ABCA1,s u g g e s t i n ga n
atheroprotective effect of MTX [12]. We hypothesized
that clinical use of low-dose MTX in humans can
alter blood lipid metabolism via induction of ABCA1 and
27HY.
The objective of the present study were to (1) compare
the blood lipid profile as well as gene expression of these
antiatherogenic proteins between subjects taking MTX
(MTX+) and other DMARDs (MTX-), and (2) examine
the associations among MTX dose, duration and lipid
profiles, as well as the expression of ABCA1 and HY27 in
the peripheral blood mononuclear cells (PBMCs) of
humans with chronic inflammation.
Methods
Subjects
A total of 100 adults (aged above 18 years) with
rheumatoid arthritis fulfilling the American College of
Rheumatology 1987 revised criteria for rheumatoid
arthritis [13] were recruited prospectively from the
Allergy, Immunology and Rheumatology outpatient clinic
at the Department of Immunology and Rheumatology,
Taichung Veterans General Hospital, Taiwan between
2007 and 2009. The study protocol was approved by the
clinical research ethics committee, and informed consent
was obtained from each participant prior to enrollment.
Subjects with pregnancy, anemia (hemoglobin 10 mg/dL
or lower), thrombocytopenia (platelet count below 50,000
cells/μL), abnormal serum hepatic transaminase (aspar-
tate aminotransferase or alanine aminotransferase above
50 IU/L), renal insufficiency (serum creatinine above
1.5 mg/dL), diabetes or cancer were excluded. None of
the study subjects were using antihyperlipidemic drugs
during the study period. Blood chemistry and hematology
screening were performed to ensure eligibility before
enrollment. All patients were taking medications for
rheumatoid arthritis symptom relief, and therefore dis-
ease activity was controlled during the study period. No
changes in medication had been made for 1 month prior
to enrollment for any of the subjects. Levels of C-reactive
protein were determined by enzyme immunoassay [14]
(Virgo C-reactive protein 150 kit; Hemagen, Waltham,
Massachusetts, USA).
Human study experimental protocol
Subjects were asked to fast overnight for 12 h for the
study blood draw. In the following morning, fasting
blood samples from the subjects were collected into
ethylenediaminetetraacetic acid (EDTA) tubes and
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cholesterol (TC), triglyceride (TG), high-density lipopro-
tein-cholesterol (HDL-C), low-density lipoprotein cho-
lesterol (LDL-C), and for RNA extraction from the
PBMCs. Each patient was then instructed to complete
the Stanford Health Assessment Questionnaire (HAQ)
[15], which has 13 categories of questions that evaluate
how well the patient is able to perform routine activities.
Plasma lipid profiles in subjects taking MTX and other
DMARDs
Plasma total lipid was determined enzymatically with an
autoanalyzer (Hitachi 7070; Hitachi, Tokyo, Japan) using
clinical chemical kits (Wako Co, Osaka, Japan). TC, TG,
HDL-C, LDL-C were determined by Randox reagent kit
(Randox Laboratories Ltd, Crumlin, UK).
ABCA1 and HY27 expression in human PBMCs
PBMC RNA was isolated using TRIzol (Invitrogen,
Carlsbad, CA, USA) and dissolved in nuclease-free
water. The quality of all RNA samples was checked on
a g a r o s eg e l( F i g u r e1 )a n dt h eq u a n t i t yo ft o t a lR N A
was measured by spectrophotometer. Complementary
DNA (cDNA) was copied from 2 μgt o t a lR N Au s i n g
M o l o n e ym u r i n el e u k e m i av i r u sr e v e r s et r a n s c r i p t a s e
(Promega, Madison, WI, USA) primed with oligo(dT).
Equal amounts of cDNA were taken from each reverse
transcription (RT) reaction mixture for real-time poly-
merase chain reaction (PCR) amplification [16], using
cholesterol HY27-specific primers or ABCA1-specific
primers a well as 18S as internal control primers. Real-
time PCR analysis was performed using the SYBR Green
PCR Reagents Kit (Applied Biosystems, Foster City, CA,
USA).
Dietary intake of study subjects
For assessment of dietary intake, subjects were
instructed to complete a food record, and each subject
was interviewed by a registered dietitian for validation
of the food record [17] on the day of blood collection.
A colored book with 1:1 size food photos were used to
standardize portion size among subjects. Nutrient
composition was calculated with the use of Nutritionist
Professional software (E-kitchen Business Corporation,
Taipei, Taiwan), in combination with the Taiwan food
composition table, established by the Department of
Health in Taiwan.
Statistical analysis
Statistical analyses were performed using SYSTAT soft-
ware (Version 11.0) for Windows (SYSTAT, Richmond,
CA, USA). Demographic and hematological data were
compared by Mann-Whitney U test between the two
groups. For categorical variables, differences between
two groups were assessed by c
2
test. Pearson correlation
coefficients were calculated between continuous vari-
ables including PBMC ABCA1 expression, HY27 expres-
sion, the MTX duration (months), and the MTX weekly
dose (mg) in subjects taking low dose MTX. Odds ratios
(ORs) with 95% confidence intervals (CI) for elevated
(above the median) ABCA1 orH Y 2 7gene expression
were calculated from unconditional logistic regression
models according to the MTX use or not. Results were
defined statistically significant at p <0.05.
Results
Demographic information
In all, 100 patients with rheumatoid arthritis were
enrolled. One subject dropped out due to her concerns
over a 15 mL blood draw for RNA extraction and lipid
profiles in addition to the patient’sr o u t i n em o n t h l y
blood draw for blood chemistry. Characteristics of the
99 subjects who completed the study are shown in
Table 1. In all, 67 patients (67%) used MTX, and 32
patients had never used MTX (n = 17, 17%) or discon-
tinued use of MTX for at least 2 months due to side
effects (n = 15, 15%). Other DMARDs used by these
subjects included prednisolone (88 patients, mean
weekly dose 39.4 mg), salazopyrin (84 patients, mean
weekly dose 7,000 mg), hydroxychloroquine (79 patients,
median weekly dose 1,402 mg), and non-steroidal anti-
inflammatory drugs (Table 1). There were no differences
in age, body mass index height, white blood cell or pla-
telet counts, hemoglobin, serum creatinine, alanine ami-
notransferase, C-reactive protein, mean blood pressure,
disease duration, or disease activity indicating that the
physical conditions were comparable in the two groups
(Table 1). Furthermore, there were no differences in the
treatment duration or weekly dose of prednisolone,
salazopyrin, hydroxychloroquine, or non-steroidal
6
6
Figure 1 The integrity and quality of all RNA samples were checked on agarose gels before being reverse transcribed.
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impacts on the biochemical parameters from other
drugs were minimal. Doses and durations of medication
used by the study subjects are shown in Table 1. The
median weekly dose of MTX used in the subjects was
12.5 (mean ± SD = 10.3 ± 3.9 mg/week), which is
slightly higher than that of our previous studies in the
US [14,18,19].
Plasma lipid profiles in subjects with or without low-dose
MTX treatments
Mean TC, TG, HDL-C, and LDL-C levels of the study
subjects were within the normal range of healthy
humans (TC <200 mg/dl; TG <150 mg/dl; HDL-C
>40 mg/dl; LDL-C <130 g/dl). Among these subjects,
24.5% had elevated plasma TC, 6.1% had elevated TG,
5.1% had low HDL-C, and 13.2% had elevated LDL-C.
No differences were detected in plasma TC, TG, HDL-
C, LDL-C in non-MTX users and subjects taking MTX
(MTX+) (Table 2). The associations among blood lipid
profile indices were examined. Plasma TC correlated
with TG (r = 0.36, p < 0.001, n = 99), with HDL-C
(r = 0.387, p < 0.001, n = 99), and LDL-C (r = 0.874,
p < 0.001, n = 99). Plasma TG concentrations correlated
with LDL-C (r = 0.367, p < 0.001, n = 99) and inversely
correlated with HDL-C (r = -0.306, p = 0.002, n = 99).
Table 1 Demographic data of study subjects (n = 99)
Characteristics Reference value/range Non-MTX users (n = 32) MTX users (n = 67) P value
a
Male/female 8/24 10/57
Age, years 53.0 (49.0 to 58.0) 53.0 (50.3 to 57.0) 0.979
BMI, kg/m
2 18.5-23.9 22.8 (21.6 to 24.4) 21.8 (21.6 to 23.5) 0.725
WBC count, cells/mm
3 5,000-10,000 6,400 (5,536 to 6,844) 5,900 (5,980 to 6,900) 0.745
Hb, g/dl 12-16 12.9 (11.7 to 13.2) 12.6 (12.2 to 12.9) 0.765
Serum creatinine, mg/dl <1.4 0.90 (0.87 to 1.13) 0.80 (0.79 to 0.87) 0.222
ALT, IU/L 0-40 15.0 (15.0 to 29.1) 16.0 (15.3 to 20.0) 0.976
CRP (mg/dL) <0.3 0.40 (0.53 to 1.65) 0.22 (0.52 to 1.75) 0.161
Systolic BP, mmHg <140 130.0 (123.4 to 133.8) 129.0 (114.7 to 142.2) 0.634
Diastolic BP, mmHg <90 80.0 (76.2 to 82.3) 79.0 (65.8 to 92.7) 0.732
Disease duration, years 14.1 (11.5 to 16.8) 12.0 (11.3 to 15.0) 0.456
Disease activity, HAQ 0.187 (0.11 to 0.80) 0.125 (0.20 to 0.49) 0.917
Physical activity, h/week 0.00 (0.37 to 3.85) 0.50 (1.14 to 2.41) 0.552
Methotrexate:
Weekly dose, mg NA 12.5 (10.5 to 12.5)
Duration, months NA 36.0 (45.8 to 77.8)
Prednisolone users/total: 24/32 (75%) 64/67 (95.5%)
Weekly dose, mg 43.7 (35.0 to 48.7) 35.0 (38.9 to 55.3) 0.167
Duration, months 34.0 (32.6 to 105.8) 48.0 (46.4 to 79.2) 0.180
Salazopyrin, users/total: 26/32 (81.25%) 58/67 (86.56)
Weekly dose, mg 7,000 (7,882 to 11,233) 7,000 (9,051 to 11,825) 0.395
Duration, months 53.5 (38.8 to 105.1) 50.0 (51.5 to 86.4) 0.848
Hydroxychloroquine: 22/32 (68.75%) 57/67 (85.07%)
Weekly dose, mg 1,404 (1,404 to 1,968) 1,400 (1,486 to 1,804) 0.241
Duration, months 11.5 (9.2 to 15.7) 13.0 (13.6 to 21.6) 0.644
Celebrex, users/total: 19/32 (59.37) 42/67 (62.68%)
Weekly dose, mg 1,400 (1,581 to 2,250) 1,400 (1,561 to 2,005) 0.660
Duration, months 18.0 (14.0 to 30.8) 23 (-8.7 to 123.8) 0.829
Meloxicam, users/total: 10/32 (31.3%) 26/67 (38.8%)
Weekly dose, mg 105 (78.6 to 110.3) 105 (78.8 to 98.8) 0.336
Duration, months 7.5 (0.78 to 23.6) 12.0 (9.6 to 27.4) 0.599
Results are expressed as median (95% CI) (n = 99).
aData were analyzed by Mann-Whitney U test.
ALT = alanine aminotransferase; BMI = body mass index; BP = blood pressure; CRP = C-reactive protein; HAQ = Health Assessment Questionnaire; Hb =
hemoglobin; WBC = white blood cells.
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and MTX(-) subjects when examined separately. The
lipid profile also reflected the health status: BMI signifi-
cantly related to TG (r = 0.397, p < 0.001, n = 99),
LDL-C (r = 0.267, p = 0.007, n = 99) and inversely
related to HDL-C (r = -0.227, p = 0.024, n = 99) con-
centrations. BMI significantly related to TC (r = 0.276,
p = 0.024, n = 67), TG (r = 0.425, p < 0.001, n = 67),
and LDL-C (r = 0.313, p = 0.010, n = 67) in the MTX
(+) subjects. BMI inversely correlated with HDL-C
(r = -0.383 p = 0.03, n = 32) in MTX(-) subjects.
ABCA1 and HY27 expression in human PBMCs
Expressions of ABCA1 and HY27 were compared. The
distributions of ABCA1 and HY27 gene expression in
MTX(-) and MTX(+) subjects are shown in Figure 2a,b,
respectively. In the PBMCs, MTX(+) subjects had signif-
icantly increased expressions of ABCA1 and HY27
mRNA compared to MTX(-) subjects (Mann-Whitney
U test, p = 0.021 and 0.037 for ABCA1 and HY27,
respectively).
No significant correlation was found between the
M T Xw e e k l yd o s eo rd u r a t i o na n dt h ee x p r e s s i o n
levels of HY27; however, an association between
ABCA1 expression and the weekly dose of MTX was
observed in MTX(+) subjects (r = 0.205, p = 0.042,
n = 67). However, when using the median expression
level as the cut-off for elevated gene expression, it was
found that MTX(+) subjects were more likely to have
elevated HY27 expression than MTX(-) subjects (OR =
2.5, p = 0.038) (Table 3). These results imply that
HY27 expression in PBMCs might be induced by MTX
treatment regardless of the dose or duration of MTX.
The PBMC expression of ABCA tended to correlate
with HY27 in all subjects (r = 0.172, p = 0.088, n =
99). In addition, ABCA expression tended to inversely
correlate with HDL-C in MTX(+) subjects (r = -0.224,
p = 0.068, n = 67).
Dietary intake
Dietary intake of calories, fat, or cholesterol did not dif-
fer between MTX(-) and MTX(+) subjects (Table 4).
Daily intake of energy (kcal/day), carbohydrate (g/day),
protein (g/day), fats (g/day), and cholesterol (mg/day)
were calculated and compared with the general popula-
tion of the same age group. The percentage energy con-
tributions from fats, protein, and carbohydrate were
28.6%, 13.3%, 58.1% in females and 25.5%, 13.5%, 61.0%
in males, respectively. The percentage of energy contri-
butions from fats, protein, and carbohydrates were
34.9%, 15.6% and 49.6%, respectively, in females or
males between the ages of 35-54 [20,21]. In comparison
with the general population of the same age group in
the Nutrition and Health Survey in Taiwan (NAHSIT)
[20-22], our subjects derived a lower percentage of
energy from fats but more energy from carbohydrates
(Table 4).
Most subjects (approximately 80%) of the present
study had a daily cholesterol intake below 300 mg and
only 7% had high fat intake (>65 g/day). These results
indicated that our subjects had relatively healthy dietary
habits, which may have contributed to the relatively nor-
mal blood lipid profiles in these subjects compared to
those of the general healthy population [20-22]. The
average time of physical activity (h) did not differ
between the two groups.
Discussion
This study demonstrated that clinical use of MTX for
treating rheumatoid arthritis is associated with elevated
expressions of atheroprotective protein HY27 and
ABCA1 in human PBMCs. This is the first in vivo evi-
dence in humans that the commonly used low-dose
MTX in rheumatoid arthritis might induce the mRNA
expression of antiatherogenic reverse cholesterol trans-
porter expression in humans. Via the induction of these
proteins, low-dose MTX treatment has the potential to
Table 2 Blood lipid profiles and cholesterol metabolic gene expressions in study subjects
Normal range Non-MTX users (n = 32) MTX users (n = 67) P value
a
TC, mg/dl ≤200 mg/dl 167.5 (162.8 to 192.4) 172.0 (169.3 to 185.5) 0.367
TG, mg/dl ≤150 mg/dl 81.0 (75.7 to 105.1) 71.0 (73.2 to 90.7) 0.344
TC/HDL-C <4 1.34 (1.25 to 1.71) 1.38 (1.30 to 1.59) 0.884
HDL-C, mg/dl ≥60 mg/dl 66.0 (59.4 to 71.8) 69.0 (65.0 to 74.0) 0.410
LDL-C, mg/dl ≤100 mg/dl 85.7 (79.6 to 102.6) 89.0 (85.8 to 99.9) 0.673
LDL-C/HDL-C 2.72 (2.51 to 3.07) 2.60 (2.53 to 2.88) 0.736
ABCA/18S 0.09 (0.03 to 0.77) 0.15 (0.43 to 2.60) 0.021
HY27/18S 0.07 (-0.05 to 1.41) 0.19 (0.32 to 5.40) 0.037
Results are expressed as median (95% CI) (n = 99). Normal ranges of plasma lipid profiles: TC (total cholesterol) ≤200 mg/dl; TG (triglyceride) ≤150 mg/dl;
HDL-C (high-density lipoprotein-cholesterol) ≥60 mg/dl; LDL-C (low-density lipoprotein-cholesterol) ≤100 mg/dl.
aData were analyzed by Mann-Whitney U test. Bold text in tables represent significantly different (p < 0.05).
ABCA1 = ATP-binding cassette transporter A1; HY27 = 27-hydroxylase; MTX = methotrexate.
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Figure 2 Expressions of ATP-binding cassette transporter A1 (ABCA1) and 27-hydroxylase (HY27) in the peripheral blood mononuclear
cells (PBMCs) of methotrexate (MTX)(-) and MTX(+) subjects. (a) The distributions of PBMC ABCA1 expression in MTX(-) and MTX(+) subjects.
(b) The distributions of PBMC HY27 expression in MTX(-) and MTX(+) subjects. The bars in the figures represent the median values of ABCA1 and
HY27 in each study group.
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lesterol outflow in patients on this medication.
In the present study, no significant differences in
blood lipids were observed between MTX(+) and
MTX(-) subjects, possibly attributed to low prevalence
of dyslipidemia in the study subjects. Although no dif-
ferences were observed in the blood lipid profiles, the
potential impacts of MTX on cholesterol metabolism
should not be overlooked. The majority of our subjects
had relatively normal cholesterol intake, and their lipid
indicators fell within the normal range of healthy
humans. We suggest that the potential impacts of
altered HY27 and ABCA1 might be compensated by
relatively normal cholesterol intake in these subjects. It
is plausible that the potential atheroprotective effects
from HY27 and ABCA1 inductions occur only in those
persons with elevated blood lipids. This postulation
needs to be investigated further in animals or subjects
with abnormal blood lipids in the future.
According to the latest 2005-2008 NAHSIT, the pre-
valence of hyperlipidemia, hypertriglyceridemia, elevated
LDL-C, and low HDL-C in females at the same age
group were 4.7%, 11.8%, 18.6%, and 2.9%, respectively
[22]. The prevalence of abnormal lipid profiles was
determined by the standard for the threshold limit value
of disease (TC ≥240 mg/dl, TG ≥200 mg/dl, HDL-C
<35 mg/dl, LDL-C≥160 g/dl) [22]. When the same stan-
dard was applied to subjects in the present study, less
than 5% of our subjects had elevated TC (4%) or TG
(2%), elevated LDL-C (2%) or low HDL-C (2%), indicat-
ing that the prevalence of abnormal blood lipid profile in
these subjects was indeed lower than that of the general
Taiwanese population of the same age. When we looked
at the prevalence of marginal elevated blood lipid profiles
using the normal range of healthy humans (mean TC
<200 mg/dl; TG <150 mg/dl; HDL-C >40 mg/dl; LDL-C
<130 g/dl), the prevalence of dyslipidemia in our subjects
was also lower than that in the NAHSIT [22]. Only 24.2%
of our subjects had elevated TC, 6.1% had elevated TG,
5 . 1 %h a dl o wH D L - C ,a n d1 2 . 1 %h a de l e v a t e dL D L - C .
Consistently, we found a lower prevalence of being over-
weight (24≤BMI <27 kg/m
2)a n do b e s i t y( ≥27 kg/m
2)i n
our study subjects (19% for being overweight and 16% for
obesity) that was also lower than that of the general
population at a similar age (39% for being overweight
and 23% for obesity) in Taiwan [22].
The therapeutic strategies for dyslipidemia include a
healthy diet with reduced intake of saturated fat and
Table 3 Stratified analysis between methotrexate (MTX) use and elevated ATP-binding cassette transporter A1
(ABCA1) and 27-hydroxylase expression in study subjects
Category Logistic regression
Low (≤median) High (>median) OR (95% CI) P value
ABCA1/18S:
MTX
No (n = 32) 20 (62.5%) 12 (37.5%) 1.00
Yes (n = 67) 31 (46%) 36 (54%) 1.94 (0.82 to 4.58) 0.13
27-Hydroxylase/18S:
MTX
No (n = 32) 21 (66%) 11 (34%) 1.00
Yes (n = 67) 29 (43%) 38 (57%) 2.50 (1.04 to 6.01) 0.038
Values represent N (%). Logistic regression results are expressed as OR (95% confidence interval) (n = 99).
Table 4 Dietary intake in study subjects
Dietary intake Reference value Non-MTX users (n = 32) MTX users (n = 67) P value
a
Energy, kcal/day 2,000 1,248 (1,158 to 1,507) 1,249 (1,184 to 1,419) 0.862
Carbohydrate, g/day 300 183.5 (155.9 to 275.2) 174.5 (174.2 to 216.9) 0.994
Percentage of energy 60% 58.65% 55.94%
Protein, g/day (50) 51.1 (19.9 to 141.0) 38.9 (38.3 to 45.8) 0.849
Percentage of energy 10% 16.39% 12.48%
Fat, g/day (65) 43.9 (11.0 to 133.8) 38.6 (36.2 to 45.0) 0.505
Percentage of energy <30% 31.68% 27.88%
Cholesterol, mg/day (<300) 243.8 (109.4 to 178.4) 223.6 (77.1 to 516.1) 0.493
Results are expressed as median (95%CI) (n = 99).
aData were compared between methotrexate MTX- and MTX+ subjects by Mann-Whitney U test.
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our subjects (79.6%) had a daily cholesterol intake below
300 mg (Table 4). In addition, only approximately one-
fifth of these subjects had fat intake exceeding 30% of
their total calories and, on average, 29% of the total
energy came from fat. In the general population of the
same age, the prevalence of high fat intake was up to
46.5%, and the energy from fats was 35% [22]. The
mean intake of saturated fat in our study subjects was
also significantly lower than that of the population [22].
We concluded that lower cholesterol and fat intake
accounted for the relatively normal blood lipid profiles
in these subjects.
In vitro MTX treatment was shown to increase HY27
mRNA expression [12] and reverse the COX2 inhibitor-
induced downregulation of HY27 and ABCA1 in human
THP-1 monocyte/macrophages [12]. Despite no differ-
ences being observed in the blood lipid profiles between
MTX(-) and MTX(+) subjects, we found that clinical
use of low-dose MTX was associated with increased
HY27 and ABCA1 mRNA in the PBMCs. These results
implied that under certain conditions, clinical use of
MTX might induce the gene expression of atheroprotec-
tive protein HY27 and ABCA1.T h i si st h ef i r s tin vivo
evidence that the commonly used DMARD MTX may
increase the expression of antiatherogenic reverse cho-
lesterol transport protein in human PBMCs. However,
the potential impacts of MTX induced HY27 and
ABCA1 expressions might be compensated by relatively
normal to low cholesterol intake in these subjects; and
that the potential atheroprotective effects from HY27
and ABCA1 m a yo n l yb ep r e s e n ti nt h o s ep e r s o n sw i t h
pre-existing dyslipidemia. Whether MTX induced HY27
and ABCA1 expressions can protect against cardiovascu-
lar disease in patients with chronic inflammation
through the facilitation of cholesterol export remains to
be established. Further studies pertaining to the poten-
tial benefits of low-dose MTX in hypercholesterolemic
subjects are warranted.
Conclusions
We demonstrated novel findings on the increased gene
expressions of atheroprotective protein HY27 and
ABCA1 in human PBMCs in subjects taking low-dose
MTX for treating chronic inflammation. Although there
is no direct evidence from this study that MTX may
improve lipid profile, this is the first in vivo evidence in
humans that the commonly used low-dose MTX in
rheumatoid arthritis might induce the mRNA expres-
sions of antiatherogenic reverse cholesterol transporters
in humans. Via the induction of these proteins, low-
dose MTX treatment has the potential to protect against
dyslipidemia through facilitation of cholesterol outflow
in patients on this medication. Further studies on the
impacts of low-dose MTX on hypercholesterolemia are
underway.
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